Zevra Therapeutics, Inc. ZVRA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.89M+1,323% | $12.17M+134% | -$544K+98.4% | $74.71M+475% | -$3.1M+81.4% | ||
| $368K-77.7% | $362K-78.0% | $392K-75.8% | $1.65M+5.7% | $1.65M+5.6% | ||
| $3.11M-0.3% | $4.28M+6.6% | $2.77M-54.8% | $2.46M-6.4% | $3.12M+47.0% | ||
| $43.31M— | —— | —— | —— | $0— | ||
| $185K-9.8% | $525K-88.9% | $194K-66.7% | $381K-61.6% | $205K-92.1% | ||
| -$529K+92.7% | $0— | -$4.73M-138% | -$4M-209% | -$7.27M+0.6% | ||
| -$2.05M-618% | -$3.79M— | $3.05M+453% | $582K-28.9% | -$286K-750% | ||
| $416K-25.7% | -$5.98M-421% | $2.83M+308% | $1.43M+127% | $560K+288% | ||
| $341K-48.6% | —— | —— | —— | $663K— | ||
| $118K— | —— | —— | —— | $0-100% | ||
| -$2.76M— | —— | —— | —— | $0— | ||
| -$123K+35.3% | -$129K+44.2% | -$1.29M-1,004% | $936K+732% | -$190K-46.2% | ||
| -$6.89M-427% | $6.37M— | —— | $4.86M— | $2.11M+123% | ||
| $6.14M+175% | —— | —— | -$3.6M+81.2% | -$8.22M+49.1% | ||
| $35K-64.6% | $0— | $554K— | $213K— | $99K— | ||
| $58.3M+692% | $87.16M+112% | $65.11M+50,574% | $150.35M+116,453% | $7.36M— | ||
| $93.97M+422% | $87.5M+43,217% | $60.5M+505% | $12.5M— | $18M+21.7% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $42K— | —— | —— | —— | $0— | ||
| $43.94M— | —— | —— | —— | $0— | ||
| $79.62M+655% | $227K+104% | —— | $11.93M+9,351% | $10.54M-28.7% | ||
| $60.09M— | $0— | $0— | $0-100% | $0— | ||
| $752K— | $0— | -$2.95M-105% | $2.95M— | $0-100% | ||
| $2.64M— | —— | —— | —— | —— | ||
| -$52.8M-3,386% | $2.55M+220% | $6.53M-89.9% | $1.38M-91.0% | $1.61M+32.0% | ||
| $233K+163% | —— | $64K+113% | $658K+106% | -$372K-727% | ||
| $33.19M+834% | $7.97M+139% | $6.73M-54.5% | $10.37M+389% | $3.56M+1,877% | ||
| $1.37M+4.9% | $1.34M-16.1% | $1.37M-10.9% | $1.32M-33.8% | $1.31M+833% | ||
| $624K+105% | $857K-3.7% | $1.21M— | $755K— | $305K— | ||
| $9.02M— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | —— | $75K— | ||
| $1.15M-39.9% | —— | $1.47M-31.8% | $1.14M— | $1.91M— | ||
| $216K+7,100% | -$30K-137% | -$124K-37.8% | $2K+300% | $3K-88.9% | ||
| -$7.22M— | —— | —— | —— | $0— | ||
| -$968K+80.1% | -$3.56M— | $5.51M+16.0% | $747K+113% | -$4.87M— | ||
| $1.4M+759% | -$1.42M-1,875% | —— | —— | -$213K+7.0% | ||
| $6.91M+485% | $501K-96.7% | —— | $2.2M— | $1.18M— | ||
| -$6.89M-427% | $6.37M— | —— | $4.86M— | $2.11M+123% | ||
| -$123K+35.3% | -$129K+44.2% | -$1.29M-1,004% | $936K+732% | -$190K-46.2% | ||
| $0+100% | —— | -$1.27M-1,300% | $964K— | -$166K— | ||
| $416K-25.7% | -$5.98M-421% | $2.83M+308% | $1.43M+127% | $560K+288% | ||
| $87K— | —— | —— | —— | $0— | ||
| -$2.05M-618% | —— | $3.05M— | $582K-28.9% | -$286K-750% | ||
| -$4.39M— | —— | —— | —— | $0— | ||
| $485K— | $0-100% | $0-100% | $11.7M+266% | $0-100% | ||
| $118K— | —— | —— | —— | $0-100% | ||
| $3.13M— | —— | —— | —— | $0— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $58.3M+692% | $87.16M— | $65.11M+57.4% | $150.35M+116,453% | $7.36M— | ||
| $93.97M+422% | $87.5M+43,217% | $60.5M+505% | $12.5M— | $18M+21.7% | ||
| $42K— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | —— | $372K— | ||
| $752K-62.0% | —— | —— | —— | $1.98M— | ||
| $9.17M— | $2.68M— | —— | —— | $0— | ||
| $60.09M— | $0— | $0— | $0-100% | $0— | ||
| $233K+163% | —— | $64K+113% | $658K+106% | -$372K-727% | ||
| -$123K+35.3% | -$129K+44.2% | -$1.29M-1,004% | $936K+732% | -$190K-46.2% | ||
| $0-100% | —— | —— | —— | $1.12M— | ||
| $5M— | —— | —— | —— | $0— | ||
| $6.11M+173% | —— | —— | -$3.81M+80.0% | -$8.32M+48.5% | ||
| $6.11M+173% | —— | —— | -$3.81M+80.0% | -$8.32M+48.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Zevra Therapeutics, Inc. generate?
- Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
- What is Zevra Therapeutics, Inc.'s free cash flow?
- After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
- Where does Zevra Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
